NCT02999477 2026-01-29
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
10 trialsNCT04306900 2025-07-29
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT02047500 2025-05-11
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
Phase 1 Terminated
NCT04581343 2025-05-04
PanCAN-SR1
Pancreatic Cancer Action Network
Phase 1 Completed
NCT05267470 2025-03-25
FORTITUDE-201
Amgen
Phase 1 Terminated
NCT02873598 2022-12-19
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
University of Colorado, Denver
Phase 1 Completed
NCT02608229 2021-04-21
BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Washington University School of Medicine
Phase 1 Terminated
NCT02622074 2020-09-10
KEYNOTE 173
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT01822756 2018-02-12
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated